Vaccine News and Research

Latest Vaccine News and Research

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

Polio immunization campaign begins across West and Central Africa

More than 85 million children under five years old will be immunized against polio in 19 countries across West and Central Africa in a massive example of cross-border cooperation aimed at stopping a year-long polio epidemic.

10 Mar 2010

Bavarian Nordic' Annual Report 2009

Today Bavarian Nordic published the company's Annual Report 2009. The report is available on the company's website: www.bavarian-nordic.com

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Insulin resistance in Hepatitis C patients: Mostly in muscle and not in liver

We have known for several years that Hepatitis C, a common cause of liver cirrhosis and cancer, also makes people three to four times more likely to develop Type 2 diabetes.

10 Mar 2010

Researchers take first step in development of vaccine against pregnancy-associated malaria

By managing to express the protein that enables red blood cells infected with the malaria agent Plasmodium falciparum to bind to the placenta and by deciphering its molecular mechanisms, a team of researchers from CNRS and the Institut Pasteur has taken an important first step in the development of a vaccine against pregnancy-associated malaria.

10 Mar 2010

Selective immunization of children may help reduce community transmission of influenza

Immunizing children and adolescents with inactivated influenza vaccine resulted in reduced rates of influenza in their community compared to a similar community in which children did not receive the vaccine, suggesting that vaccinating children may help prevent transmission of the virus and offer protection for unimmunized community residents, according to a study in the March 10 issue of JAMA.

10 Mar 2010

Supreme Court to hear case on vaccine side effects

The Associated Press: The Supreme Court will hear a case to decide whether drug makers can be sued by families who claim their children have suffered health problems from vaccines, going against a 1986 federal law that shields drug makers from most lawsuits and instead sets up a federal vaccine court to handle disputes.

10 Mar 2010

Sartorius achieves operating earnings of 60.9M euros for 2009

Sartorius, a leading international laboratory and process equipment provider, increased its operating profit in 2009 despite the difficult macroeconomic climate and achieved operating earnings of 60.9 million euros, up from 56.8 million euros a year earlier. “As a result, we are among the companies that were able to close the 2009 year of crisis with a positive development of operating earnings,” commented CEO Dr. Joachim Kreuzburg on the company’s full-year results at the annual press conference in Goettingen, Germany.

From Sartorius 9 Mar 2010

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

9 Mar 2010

FDA invites "Little Women" to present research on dangers of HPV vaccines

Called the "Little Women," six women who have spent the past three years listening, documenting and researching parental concerns about Gardasil have been invited to formally present their information to the FDA on March 12. FDA participants include the Office of Communication, Outreach and Development/Center of Biologics (CBER), Office of Biostatistics and Epidemiology, and Office of Vaccines Research and Review.

9 Mar 2010

New study may lead to expansion of drug arsenal used to fight HIV

New findings from a Universit- de Montr-al and the Vaccine and Gene Therapy Institute of Florida (VGTI) study, in collaboration with scientists from the NIH and the McGill University Health Center, may soon lead to an expansion of the drug arsenal used to fight HIV.

9 Mar 2010

PDVI launches new web site for tracking dengue fever epidemics

PDVI, a program of the International Vaccine Institute funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide.

9 Mar 2010

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.

8 Mar 2010

Scientists identify the role of vitamin D in activation of T cells

Scientists at the University of Copenhagen have discovered that Vitamin D is crucial to activating our immune defenses and that without sufficient intake of the vitamin, the killer cells of the immune system - T cells - will not be able to react to and fight off serious infections in the body.

8 Mar 2010

Free online training Webinars to prepare nurses for continued relief efforts in Haiti launched

While disaster response is a highly technical and sensitive effort, the most qualified of disaster professionals require additional education or real-life experience to ensure that help is delivered effectively, safely and efficiently. To assist nursing professionals volunteering their services in Haiti, Chamberlain College of Nursing in cooperation with the Johnson & Johnson Campaign for Nursing's Future, will provide free online training Webinars hosted on the Gannett Healthcare Group's newly launched Haiti Web page to prepare nurses physically, mentally and culturally for the continued relief efforts.

6 Mar 2010

Abt Associates receives two new contracts to evaluate effectiveness of H1N1 vaccine

The Centers for Disease Control and Prevention has awarded Abt Associates two new contracts to evaluate the effectiveness of the H1N1 vaccine among health care workers and children under the age of 18.

6 Mar 2010

Lancet World Report examines GAVI's funding gap

Lancet World Report examines the challenges ahead for the GAVI Alliance, which after a decade of "steadily increasing financing" is now "facing a funding shortfall for the next decade that could hamper the roll-out of new vaccines." GAVI leaders attribute the funding challenges to the global economic crisis, which has kept government aid budgets from increasing, according to the Lancet.

6 Mar 2010